In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRISPR Therapeutics AG

www.crisprtx.com

Latest From CRISPR Therapeutics AG

Scrip Asks... What Will 2019 Hold For Biopharma? Part 1: Therapeutic Advances

Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.

Innovation Market Intelligence

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.

Financing StartUps and SMEs

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies

Editas' EDIT-101 Set To Be First In Vivo CRISPR Gene-Editing Therapy In Clinic

Editas CEO says recent IND filing to treat LCA10 eye disease puts EDIT-101 on track to be first CRISPR medicine administered directly to patients. Bosley also voices relief at recent US IP court ruling.

Business Strategies Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Hepatic (Liver)
  • Immune Disorders
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • CRISPR Therapeutics AG
  • Senior Management
  • Samarth Kulkarni, PhD, CEO
    Michael Tomsicek, CFO
    Rodger Novak, PhD, Pres.
    Lawrence Klein, PhD, Head, Bus. Dev. & Strategy
    Tony Ho, MD, Head, R&D
  • Contact Info
  • CRISPR Therapeutics AG
    Phone: 41 561 32 77
    Baarerstrasse 14
    Zug, V8 CH-6300
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register